Navigation Links
Valeant Pharmaceuticals Announces New Management Appointments
Date:11/28/2012

MONTREAL, Nov. 28, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that Ryan Weldon and Jason Hanson will be named to Valeant's Executive Management Team.  Mr. Weldon will assume the role of Executive Vice President/Company Group Chairman where he will lead the U.S. Dermatology operations, including prescription dermatology, aesthetics and podiatry. Mr. Weldon will be relocating to Arizona where these operations will be headquartered.  Mr. Hanson will relocate to New Jersey where he will assume the role of Executive Vice President/Company Group Chairman and lead certain U.S and international businesses and functions to be named later.  In addition, Vince Ippolito will be appointed Senior Vice President, General Manager, Aesthetics and Justin Smith will be appointed Senior Vice President, General Manager U.S. Rx Dermatology and both will report to Ryan Weldon in Scottsdale, AZ.  Mr. Ippolito and Mr. Smith have each held various sales and marketing leadership positions at Medicis Pharmaceutical Corporation (NYSE: MRX). These changes will be effective upon the close of Valeant's acquisition of Medicis, currently anticipated to occur on December 11, 2012.

"The Board of Directors and I are pleased to add such experienced candidates to the Valeant management team," said J. Michael Pearson, chairman and chief executive officer.  "These individuals have demonstrated exceptional operating performance at their respective companies and business units and I believe they are the right candidates to continue Valeant's growth and success in the future. We expect to be able to announce more management announcements around the time of closing."

Ryan Weldon has served as Vice President & General Manager, Aesthetics since December 2011 and Vice President & General Manager, Neurology & Other since January 2010. Mr. Weldon joined Valeant in 2008 after working for McKinsey & Co. and Johnson & Johnson.

Jason Hanson has served as Executive Vice President, Chief Operating Officer of Medicis Pharmaceutical Corporation since July 2010, and as Executive Vice President since 2006. Mr. Hanson joined Medicis in 2006 and was appointed to the position of Executive Vice President, General Counsel, and Corporate Secretary. From April 2004 to July 2006, Mr. Hanson served as General Counsel for GE Healthcare Technologies, a global business specializing in medical imaging, information technology and other durable medical equipment and services, where he was responsible for the global legal affairs of GE Healthcare Technologies and a member of the company's senior management team.

Vince Ippolito has been with Medicis for ten years where he most recently served as Executive Vice President, Sales and Marketing. During his tenure at Medicis, he has helped launch more than ten new products, including LOPROX® Shampoo, VANOS®, Restylane®, Perlane®, SOLODYN®, ZIANA® and DYSPORT®. Prior to joining Medicis, Mr. Ippolito was employed by Novartis AG.

Justin Smith has been with Medicis for fifteen years where he most recently served as Senior Vice President, Marketing for both dermatology and aesthetics products.  Most recently, Mr. Smith spearheaded Medicis' access solutions strategy and was responsible for launching SOLODYN®.  He also held senior positions in sales management. 

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Forward-Looking Statements

This press release may contain forward-looking statements. These forward-looking statements relate to, among other things, the closing of the Medicis transaction and the future roles of certain management. Forward-looking statements can generally be identified by the use of words such as "believe," "anticipate," "expect," "estimate," "intend," "continue," "plan," "project," "will," "may," "should," "could," "would," "target," "potential," and other similar expressions.  In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.  Actual results may differ materially from those expressed or implied in such statements.  Important factors that could cause actual results to differ materially from these expectations include, among other things, the satisfaction of customary closing conditions with respect to the closing of the Medicis transaction, and the risk factors as detailed from time to time in Valeant's reports filed with the Securities and Exchange Commission and the Canadian Securities Administrators. 

Contact Information: 
Laurie W. Little 
949-461-6002 
laurie.little@valeant.com

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals Announces Publication of Efinaconazole Phase III Results
2. Valeant Pharmaceuticals Annonces New $1.5 Billion Securites Repurchase Program
3. Valeant Pharmaceuticals Receives FTC Clearance For Medicis Acquisition
4. Valeant Pharmaceuticals Reports 2012 Third Quarter Financial Results
5. Valeant Pharmaceuticals Reschedules Its Third Quarter 2012 Financial Results Webcast And Conference Call To November 2, 2012 Due To Hurricane Sandy
6. Valeant Pharmaceuticals International, Inc. Announces Pricing Of Concurrent Private Offerings Of Senior Notes
7. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
8. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
9. Valeant Pharmaceuticals To Syndicate Incremental Loans
10. Valeant Pharmaceuticals Announces Management Change
11. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... AccuGenomics, Inc., a diagnostic company based in ... the company has provided an AccuKit to the HIV ... Chapel Hill and to Qura Therapeutics for evaluation in ... HIV reservoir and viral expression in human CD4+ T ... Center is a joint initiative between the University of ...
(Date:8/8/2017)... Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a ... reports its financial results for the second quarter ended ... the second quarter 2017 and to date: ... development programs for the Company,s lead project, BL-8040: ... study with BL-8040 as novel stem cell mobilization treatment ...
(Date:8/7/2017)... 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest ... June 30, 2017.  All comparisons, unless otherwise noted, are to ... Second Quarter 2017 Highlights include: ... an increase of 3.5% Total prescriptions dispensed ... of 7.5% versus 7.6% Gross profit ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... August 18, 2017 , ... More than 20,000 pairs of ... Congo (DRC) thanks to an ambitious venture that conjoined the passions of an NBA ... support of the Liberty community. These shoes will save lives from the rampant infections ...
(Date:8/18/2017)... ... August 18, 2017 , ... Mediaplanet today announces the launch ... lifestyles and highlighting the importance of proactive eye and ear health. The campaign ... latest innovations in hearing aid technology. , In this issue, the National ...
(Date:8/18/2017)... , ... August 18, 2017 , ... ... handling handheld devices. Through an educational webinar, they will present the line of ... chance to learn how easy you can automate everyday pipetting tasks. , Ideal ...
(Date:8/18/2017)... ... 2017 , ... Radabaugh & Associates, a family managed agency ... West Virginia, is embarking on a cooperative charity effort with the Chestnut Mountain ... Chestnut Mountain Ranch (CMR) is a Christ-centered boarding school for young men offering ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Brian Gifford Agency, an ... is campaigning in support of Campagna Academy in a charity drive to provide for ... Boys’ Town of Indiana,” Campagna Academy is a nonprofit organization that has offered critical ...
Breaking Medicine News(10 mins):